Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One RNAi-Related Patent Application: Apr 12, 2007

Title: Bioinformatically Detectable Group of Novel Vaccina Regulatory Genes and Uses Thereof
Number: 20070077553
Filed: Oct. 30, 2003
Inventor: Isaac Bentwich, Rosetta Genomics
The invention “relates to a group of novel viral RNA regulatory genes, here identified as viral genomic address messenger genes or VGAM genes, and as viral genomic record or VGR genes,” according to the patent application’s abstract. “VGAM genes selectively inhibit translation of known host target genes and are believed to represent a novel pervasive viral attack mechanism. VGR genes encode an operon-like cluster of VGAM genes. VGAM and viral VGR genes may therefore be useful in diagnosing, preventing and treating viral disease,” the abstract adds. “Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.”

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.